Loading…
← CockpitCompetitor Analysis › 2509.HK Qyuns Therapeutics Co., Ltd. Class HOpen in the cockpit ↗

Qyuns Therapeutics Co., Ltd. Class H2509.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum neutral 48
Mkt cap
$428M
US dollars, full cap
Free float
6%
of shares outstanding
$/day
$168,015
20-day average traded
Fwd P/E
10.2×
forward earnings
ROIC−WACC
+87.9 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · HKDHK$14.59
1D-0.1%
1W-0.1%
1M-8.8%
3M-17.0%
6M-10.8%
YTD-22.3%
1Y-24.2%
ATR %4.5%
52w lowhigh40.5% off high

What Qyuns Therapeutics does

Employees: 337

Qyuns Therapeutics at a glance

Size Qyuns Therapeutics (2509.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $428M, the 782nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$14.59 on 18 Nov 2026.

Performance Over six months the shares fell 10.8%, against -22.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 230.3% over the last twelve months (peer median +1.7%); the operating margin is 56.4% (peer median -17.2%).

Valuation It trades at 10.2× forward earnings against a peer median of 33.9× (2nd cheapest of 6).

Capital Return on invested capital runs 87.9 points above its cost of capital (6.9% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 20262509.HK 91Peer median 78
Six months, rebased to 100: Qyuns Therapeutics against the median of its 20 peers (local-currency closes).

Qyuns Therapeutics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.14BHK$875MHK$172MHK$0HK$0
Revenue growth—+408%———
Gross profitHK$989MHK$740MHK$64.5M-HK$35.7M-HK$35.5M
EBITDAHK$679MHK$391M-HK$354M-HK$549M-HK$353M
Net incomeHK$607MHK$341M-HK$364M-HK$561M-HK$347M
Free cash flowHK$549MHK$414M-HK$214M-HK$352M-HK$299M
Capital expenditureHK$16.2MHK$8.27MHK$1.91MHK$8.78MHK$26.5M
Total debtn/aHK$646MHK$561MHK$381MHK$331M

Quarterly statements and history in the cockpit →

Qyuns Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%PRTA671265476883171789603739000710476830CADLIRLA456160688163EPRXARVN68823865896998337811518011672509.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Qyuns Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×150×67126547178911672509.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qyuns Therapeutics is the large dot.

Qyuns Therapeutics competitors and peer comparison

How Qyuns Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qyuns Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure2509.HKPeer medianRank in peer set
1-month return-8.8%-13.4%7th highest of 21
6-month return-10.8%-22.5%9th highest of 21
Distance from 52-week high-40.5%-46.2%10th highest of 21
Revenue growth (TTM)+230.3%+1.7%4th highest of 17
Operating margin56.4%-17.2%2nd highest of 17
Forward P/E10.2×33.9×2nd cheapest of 6
Growth the price implies (Req g, 7 yrs)-19.5%3.0%least demanding of 7
ROIC minus cost of capital+87.9 pp-12.7 pphighest of 16
EV / EBITDA4.4×n/a—
Net debt / EBITDA-0.6×-5.5×most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%10.2×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%n/an/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%26.2×5.3%+70.5%
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%39.4×2.1%+0.5%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%

Questions

Which companies are Qyuns Therapeutics's closest peers?
The cockpit's peer set: Prothena (PRTA), Ever Supreme Bio Technology (6712.TWO), Medigen Vaccine Biologics (6547.TWO), Shanghai ZJ Bio-Tech (688317.SS), Scinopharm Taiwan (1789.TW), Qingdao Vland Biotech (603739.SS), Berry Genomics (000710.SZ), Rznomics (476830.KS).
Is Qyuns Therapeutics expensive compared with its peers?
On forward p/e it trades at 10.2× against a peer median of 33.9×, 2nd cheapest of 6 in its peer set.
How has Qyuns Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -10.8% against -22.5% for the median peer; over one year -24.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.